Experimental Medications for Improving Heart Function After STEMI
While several experimental therapies have been investigated, bone marrow-derived stem cell therapy and intravenous metoprolol show the most promise for improving left ventricular function after STEMI, though neither is currently part of standard guideline-recommended care.
Current Experimental Approaches
Bone Marrow-Derived Cell Therapy
The most extensively studied experimental approach involves intracoronary injection of bone marrow mononuclear cells (BM-MNC). The REPAIR-AMI trial demonstrated that patients receiving BM-MNC 3-7 days after successful primary PCI showed significantly greater improvement in left ventricular ejection fraction compared to placebo (5.5% vs 3.0% increase at 4 months, p=0.01) 1.
More importantly, this improvement appears durable: A 5-year follow-up study showed sustained LVEF improvement in the BM-MNC group (+7.95%) while the control group showed no improvement (-0.5%, p=0.035 for interaction) 2. The treated group also experienced reduced rates of reinfarction (0% vs 5.8%) and need for revascularization (22% vs 36%) 1.
However, critical caveats exist: Two other randomized trials of BM-MNC in STEMI reported negative or mixed results, possibly due to differences in cell processing, storage, and functionality 1. A 2026 meta-analysis of 8 RCTs (796 patients) confirmed modest LVEF improvement (WMD 3.18%, 95% CI: 1.52-4.83) but found no reduction in mortality, heart failure hospitalization, or major adverse cardiac events 3.
Bottom line: Large-scale, placebo-controlled trials adequately powered for clinical outcomes are still required before this can be recommended 1.
Intravenous Metoprolol
The METOCARD-CNIC trial showed that IV metoprolol (35 mg) administered in the ambulance prior to primary PCI in anterior STEMI patients reduced infarct size, prevented adverse LV remodeling, preserved LV function, and lowered hospital readmissions for heart failure 4.
However, conflicting evidence emerged: The EARLY BAMI trial failed to show MI size reduction at 1 month with IV metoprolol (25 mg) prior to PCI 4. Key differences included lower dosing (10 vs 15 mg initial bolus), timing variations, and different patient populations (all-comers vs anterior STEMI only).
This approach is not suitable for all patients—those with heart failure, hypotension, or AV-block are excluded 4. The ongoing MOVE ON! trial will determine whether this improves clinical outcomes (cardiac death and heart failure hospitalization).
Other Investigated Therapies
Drugs targeting mitochondrial function: A 2017 meta-analysis of 15 studies (5,680 patients) found these agents reduced heart failure hospitalization (OR 0.64) and increased LVEF (OR 1.44) but did not reduce mortality 5. Interestingly, only drugs with indirect/unspecific mechanisms showed mortality benefit, while those with direct/selective mitochondrial action showed no benefit.
Remote ischemic conditioning (RIC): Limb RIC showed positive results in some proof-of-concept studies, with one trial showing reduced major adverse cardiac events and mortality within 4 years 4. However, the definitive CONDI-2/ERIC-PPCI trial results are still awaited.
Cyclosporine-A: Initial promising results were not confirmed in the larger CIRCUS trial (791 patients), which failed to show MI size reduction or improved 1-year outcomes 4.
Supersaturated oxygen delivery: The AMIHOT trial showed no significant differences in infarct size or cardiovascular outcomes 1.
Minocycline: A 2022 RCT found no effect on cardiac remodeling or MMP-9 levels 6.
SGLT2 inhibitors (empagliflozin): Recent evidence suggests consistent LVEF improvement (1.5-5.7%), reduced NT-proBNP (~15%), and lower HF hospitalization risk in post-STEMI patients with reduced LVEF, though mortality benefit remains unproven 7.
What IS Standard of Care
While you asked about experimental therapies, it's crucial to emphasize that proven guideline-recommended medications dramatically improve outcomes and should never be delayed in favor of experimental approaches:
- ACE inhibitors (or ARBs if intolerant) for patients with heart failure, LVEF <40%, diabetes, or anterior infarct 8
- Aldosterone antagonists for LVEF ≤40% with heart failure or diabetes 8
- Beta-blockers for heart failure and/or LVEF <40% 8
- High-intensity statins started immediately 8
- Dual antiplatelet therapy for 12 months 8
Clinical Reality
None of the experimental therapies discussed have sufficient evidence for routine clinical use outside of research protocols. The most mature data exist for bone marrow cell therapy and IV metoprolol, but both require definitive outcome trials before clinical implementation. If your patient has reduced LV function post-STEMI, optimize guideline-directed medical therapy aggressively—this remains the only proven approach to improve morbidity and mortality.